Rossari Biotech Ltd. News and Updates

Name: Latest research reports of Rossari Biotech Ltd. authored by KRChoksey and published by - Trendlyne research reports.
Item: Rossari Biotech Ltd.
Rating: 5
Author: KRChoksey

Keep track of all breaking news on Rossari Biotech Ltd. from all sources in a single place.

Rossari Biotech Ltd.

24 Jan 2025

629.50

2.66%

Top-line to grow with the support of volume

Buy: Rossari Biotech Ltd.

Target

KRChoksey

•Rossari reported slightly lower-than-expected revenue but achieved 11% YoY growth, driven by strong execution in export markets for HPPC and textile segments, along with healthy performance in key ANH markets, despite challenging domestic conditions.
•Despite delivering lower than expected revenue, gross profit grew 16% YoY, aided by new product launches in Buzil Rossari Business.

Rossari Biotech Ltd. is trading below all available SMAs

Rossari Biotech Ltd.

23 Jan 2025

629.50

2.66%

Rossari Biotech Results Earnings Call for Q3FY25

Conference Call with Rossari Biotech Management and Analysts on Q3FY25 Performance and Outlook. Listen to the full earnings transcript.

Rossari Biotech Ltd.

22 Jan 2025

629.50

2.66%

Rossari Biotech share price falls 5% after mixed Q3 results; profit down 8%

Business Standard

The fall in Rossari Biotech came after the company reported a mixed bag of results in the December quarter of financial year 2025 (Q3FY25)

Rossari Biotech Ltd. has an average target of 939.75 from 4 brokers.

Rossari Biotech Q3 Results 2025 on 22 Jan, 2025: profit falls by 7.82% YOY, profit at 31.7 crore …

livemint | 22 Jan 2025

Rossari Biotech Ltd.

23 Oct 2024

629.50

2.66%

Rossari Biotech Confident Of 14% Revenue Growth In Fiscal 2025

NDTV Profit

Rossari Biotech's push towards the "untapped" export market has helped it balance the softening of demand in the domestic market, said CFO Ketan Sablok.

Rossari Biotech Ltd. has an average target of 939.75 from 4 brokers.

Rossari Biotech Ltd.

23 Oct 2024

629.50

2.66%

Top-line to grow with the support of volume

Buy: Rossari Biotech Ltd.

Target

KRChoksey

Rossari Biotech reported lower than expected topline and bottom line Q2FY25 due to softer HPPC growth and material weakness in TSC segment. Despite these pressures , it posted 3.1%/12%/3.2%/7.2% revenue /GP/EBITDA/PAT growth on YOY basis led by heathy export growth in the HPPC segment.